Back to News
Market Impact: 0.35
Fresenius Acquires Remaining 45% Stake In MAbxience For Up To EUR 750 Mln
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
Fresenius acquired the remaining 45% stake in mAbxience Holding for up to €750 million, taking full ownership of the business. The transaction expands Fresenius's control over its healthcare and biopharmaceutical operations, though no financial contribution or synergy targets were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
FRE0.55
More News
- Nuveen CEO on Schroders Deal, Plans for Combined Company
- $8.2B acquisition validates AI-picked chip stock: +20% since June
- Paramount promised 30 movies a year to win Warner Bros. Losing Miramax if it fails may not scare it
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Bargain Britain lures foreign buyers as hostile takeovers surge
- Onsemi revises Synaptics deal to $123/sh all-cash, shares of both soar
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard